

monitor

MOLECULES

Tetramic and tetronic acids as β -secretase inhibitors


Alzheimer's disease (AD) is a common age-related neurodegenerative disorder affecting ~2% of the population in industrialized countries. One in ten individuals over the age of 65, and nearly half of those over the age of 85, are likely to develop the disease, for which there is currently no cure. Investigation by the scientific community has provided insight into the biology of the disease and revealed several options for treatment.

Brains of patients affected by AD are characterized by two structural features: amyloid plaques and neurofibrillary tangles [1]. β -Amyloid plaques are specific for AD, whereas tangles are also found in other disorders, such as Parkinson's disease [2]. The 'amyloid hypothesis' assigns a central role to the accumulation of β -amyloid peptide ($A\beta$) in the brain for the development of the pathology [3]. $A\beta$ peptides derive from the abnormal cleavage of the β -amyloid precursor protein (β -APP). β -Secretase (BACE-1) is a member of the pepsin family of aspartyl proteases and has a crucial role in this amyloid cascade. Recent reports have demonstrated a direct correlation between increased BACE-1 activity and $A\beta$ production in AD brain tissue [4]. Because aspartic protease inhibitors have been previously developed, BACE-1 inhibition has been recognized as a tractable target from a drug-development perspective. Most of the BACE-1 inhibitors published to date share a peptidic character and mimic the scissile amide bond of the natural substrate by a non-cleavable transition state isostere. As a consequence, they display low oral bioavailability and poor blood-brain barrier permeation. Therefore, non-peptidic BACE-1 inhibitors are of great interest for AD drug development.

Recent efforts [5], using a solid phase synthesis approach on Wang resin, have identified tetronic, tetramic and N-substituted tetramic acids that can inhibit BACE-1. In this work, compounds such as the tetramic acids were synthesized from loading of Fmoc-protected amino acids onto Wang resin, followed by N-deprotection, amidation and base-catalyzed cyclisation to deliver compounds of general structure (i), as depicted in the Scheme. In this way, a small library was synthesized as

singletons and compounds screened in a FRET assay for BACE-1 inhibition. One of the most potent compounds isolated was (ii), which had an IC_{50} of 60 μ M for BACE-1 inhibition.

This work has identified a novel series of tetramic acid BACE-1 inhibitors that have low molecular weight. Thus, these are amenable to optimization to provide compounds with the potential for good oral bioavailability. They therefore serve as a useful starting point for further optimization.



- 1 LaFerla, F.M. and Oddo, S. (2005) Alzheimer's disease: A β , tau and synaptic dysfunction. *Trends Mol. Med.* 11, 170–176
- 2 Joachim, C.L. and Selkoe, D.J. (1992) The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. *Alzheimer Dis. Assoc. Disord* 6, 7–34
- 3 Selkoe, D.J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature* 399, A31–A32
- 4 Li, R. et al. (2004) Amyloid β peptide load is correlated with increased β -secretase activity in sporadic Alzheimer's disease patients. *Proc. Natl. Acad. Sci. U. S. A.* 101, 3632–3637
- 5 Larbig, G. and Schmidt, B. (2006) Synthesis of tetramic and tetronic acids as β -secretase inhibitors. *J. Comb. Chem.* 8, 480–490

Paul Edwards
mepaulewards@fsmail.net

Elsevier celebrates two anniversaries with a gift to university libraries in the developing world

In 1580, the Elzevir family began their printing and bookselling business in the Netherlands, publishing works by scholars such as John Locke, Galileo Galilei and Hugo Grotius. On 4 March 1880, Jacobus George Robbers founded the modern Elsevier company intending, just like the original Elzevir family, to reproduce fine editions of literary classics for the edification of others who shared his passion, other 'Elzevirians'. Robbers co-opted the Elzevir family printer's mark, stamping the new Elsevier products with a classic symbol of the symbiotic relationship between publisher and scholar. Elsevier has since become a leader in the dissemination of scientific, technical and medical (STM) information, building a reputation for excellence in publishing, new product innovation and commitment to its STM communities.

In celebration of the House of Elzevir's 425th anniversary and the 125th anniversary of the modern Elsevier company, Elsevier donated books to ten university libraries in the developing world. Entitled 'A Book in Your Name', each of the 6700 Elsevier employees worldwide was invited to select one of the chosen libraries to receive a book donated by Elsevier. The core gift collection contains the company's most important and widely used STM publications, including *Gray's Anatomy*, *Dorland's Illustrated Medical Dictionary*, *Essential Medical Physiology*, *Cecil Essentials of Medicine*, *Mosby's Medical, Nursing and Allied Health Dictionary*, *The Vaccine Book*, *Fundamentals of Neuroscience*, and *Myles Textbook for Midwives*.

The ten beneficiary libraries are located in Africa, South America and Asia. They include the Library of the Sciences of the University of Sierra Leone; the library of the Muhimbili University College of Health Sciences of the University of Dar es Salaam, Tanzania; the library of the College of Medicine of the University of Malawi; and the University of Zambia; Universite du Mali; Universidade Eduardo Mondlane, Mozambique; Makerere University, Uganda; Universidad San Francisco de Quito, Ecuador; Universidad Francisco Marroquin, Guatemala; and the National Centre for Scientific and Technological Information (NACESTI), Vietnam.

Through 'A Book in Your Name', these libraries received books with a total retail value of approximately one million US dollars.

For more information, visit www.elsevier.com